(Q34364927)

1 August 2017

0 references

Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials (English)

1 reference

1 August 2017

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Federica Barbagallo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Elisa Giannetta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Tiziana Feola

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Daniele Gianfrilli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Valentina Dall'Armi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Roberto Badagliacca

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Andrea Lenzi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Andrea M Isidori

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

English

0 references

publication date

20 October 2014

1 reference

1 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

6 June 2020

copyright license

start time

20 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

PDE5 inhibitor efficacy is estrogen dependent in female heart disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: Its Role in Improving Cochrane Reviews

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Controversies in ventricular remodelling

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Sildenafil citrate therapy for pulmonary arterial hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Phosphodiesterase type 5 and high altitude pulmonary hypertension.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Nitric oxide and other novel therapies for pulmonary hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

6 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Long-term use of sildenafil in the therapeutic management of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-014-0185-3

Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4201993

Effects of sildenafil citrate (Viagra) combined with nitrate on the heart

27 October 2018

1 reference

12 December 2020

A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study

1 reference

12 December 2020

Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure

1 reference

12 December 2020

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

1 reference

12 December 2020

Hemodynamic effects of sildenafil in men with severe coronary artery disease

1 reference

12 December 2020

Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?

1 reference

12 December 2020

Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction

1 reference

12 December 2020

Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy

1 reference

12 December 2020

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study

1 reference

12 December 2020

10.1186/S12916-014-0185-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

25330139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25330139%20AND%20SRC:MED&resulttype=core&format=json